Sublobar resection versus lobectomy for stage IA non–small-cell lung cancer: A systematic review and meta-analysis of randomized controlled trials

医学 肺癌 随机对照试验 荟萃分析 外科 阶段(地层学) 系统回顾 切除术 梅德林 肿瘤科 内科学 生物化学 生物 古生物学
作者
Patrick F. Meldola,Otávio A.S. Toth,Erick Schnorrenberger,Patricia Machado,G. Chiarelli,Jose L. S. Kracik,C.C. Carvalho,Matheus de M. Lôbo,Jefferson Luiz Gross
出处
期刊:Surgical Oncology-oxford [Elsevier]
卷期号:51: 101995-101995 被引量:4
标识
DOI:10.1016/j.suronc.2023.101995
摘要

Surgical resection is the first-line treatment for early-stage lung cancer, with lobectomy being the standard choice since the 1960s. Nevertheless, recent studies have shown controversies about whether sublobar resection or lobectomy is the optimal surgical approach today. In this sense, this meta-analysis aims to compare these techniques. PubMed, EMBASE, and Cochrane databases were searched for randomized controlled trials (RCTs) comparing sublobar resection with lobectomy for stage IA non-small-cell lung cancer (NSCLC) and reporting any of the following outcomes: (1) Overall survival (OS); (2) disease-free survival (DFS); and (3) total disease recurrences. Sublobar resection encompassed wedge resection and segmentectomy techniques. A total of 1975 patients from four studies were included, of whom 978 (49.5%) underwent sublobar resection and 973 (49.3%) were male. All tumors were smaller than 2 cm. Follow-up ranged from 5 to 7.3 years. Mean age was 62.8 ± 37.0 years, and 1353 (68.5%) patients had a known smoking history. OS (HR 0.79; 95% CI 0.60–1.05; p = 0.11) and DFS (HR 1.02; 95% CI 0.86–1.22; p = 0.80) did not significantly differ between the sublobar resection and lobectomy groups. Similarly, no significant statistical difference was observed in total disease recurrences (RR 1.17; 95% CI 0.93–1.46; p = 0.17). Subgroup and isolated sublobar resection techniques analyses were not possible due to the lack of data. Sublobar resection and lobectomy have similar OS, DFS, and disease recurrence rates for stage IA NSCLC. These findings underline the need for new RCTs investigating these outcomes in specific patient subgroups and isolated sublobar resection techniques.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
称心小天鹅完成签到,获得积分10
1秒前
ChenYX发布了新的文献求助10
3秒前
优雅大树完成签到,获得积分20
3秒前
Lu发布了新的文献求助10
3秒前
量子星尘发布了新的文献求助20
3秒前
笠原May发布了新的文献求助10
5秒前
搜集达人应助璃光浮月采纳,获得10
5秒前
谨慎的安柏完成签到 ,获得积分10
5秒前
5秒前
优雅大树发布了新的文献求助30
6秒前
而已完成签到,获得积分10
7秒前
cc完成签到 ,获得积分10
7秒前
7秒前
9秒前
9秒前
AquaR完成签到,获得积分10
9秒前
七月七日晴完成签到,获得积分10
10秒前
帅气爆米花应助wang采纳,获得290
12秒前
lxj发布了新的文献求助10
13秒前
13秒前
Lu完成签到,获得积分10
13秒前
香哥完成签到 ,获得积分10
13秒前
CodeCraft应助徐立涛采纳,获得10
15秒前
16秒前
卷卷卷儿完成签到 ,获得积分10
16秒前
Akim应助神奇白马儿采纳,获得10
17秒前
小文殊完成签到 ,获得积分10
17秒前
17秒前
二分三分完成签到,获得积分10
19秒前
CipherSage应助科研采纳,获得10
20秒前
追梦人发布了新的文献求助10
20秒前
可爱语芹完成签到 ,获得积分10
20秒前
猪猪hero发布了新的文献求助10
21秒前
丰知然举报jasmineee求助涉嫌违规
21秒前
guan完成签到,获得积分10
22秒前
帅气爆米花应助小翼采纳,获得30
22秒前
清茶发布了新的文献求助10
23秒前
策略完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
人脑智能与人工智能 1000
King Tyrant 720
Silicon in Organic, Organometallic, and Polymer Chemistry 500
Principles of Plasma Discharges and Materials Processing, 3rd Edition 400
Pharmacology for Chemists: Drug Discovery in Context 400
El poder y la palabra: prensa y poder político en las dictaduras : el régimen de Franco ante la prensa y el periodismo 400
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5604083
求助须知:如何正确求助?哪些是违规求助? 4688908
关于积分的说明 14856973
捐赠科研通 4696430
什么是DOI,文献DOI怎么找? 2541128
邀请新用户注册赠送积分活动 1507314
关于科研通互助平台的介绍 1471851